INBS · Intelligent Bio Solutions Inc. · Metrics
$1.58
-0.09 (-5.39%)
At close · Oct 6
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 19, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Management believes there is a material risk that the Company's cash and cash equivalents as of June 30, 2026, of approximately $3.99 million, will be insufficient to fund its current operating plan through at least the next 12 months from the issuance of these consolidated financial statements. Accordingly, the Company will be required to raise additional funds during the next 12 months. While the Company intends to obtain additional funding through equity or debt financings, strategic collaborations, or other arrangements, there can be no assurance that such funding will be available on acceptable terms, or at all. If the Company is unable to obtain additional financing when needed, it may be required to delay, reduce, or curtail the scope of its operations and development activities. In addition, the Company may be unable to realize its assets and discharge its liabilities in the normal course of business. Accordingly, these conditions raise substantial doubt about the Company's ability to continue as a going concern, unless it can successfully meet the stated objectives and/or raise additional capital.”View the 10-K filed Aug 19, 2026
Market Cap
$5.15M
Shares
3.03M
Volume · Oct 6
76.65K
Avg daily vol (3M)
157.9K
INBS metrics
55 of 115 screener metrics currently available.
Market overview
2 metricsShare price
$1.67
Market cap
$5.15M
Price action
20 metricsPrice change (1W)
-2.4%
Price change (30D)
-22.8%
Price change (3M)
-25.9%
Price change (6M)
-39.6%
Price change (YTD)
-82.6%
Price change (1Y)
—
Trailing year
Price change (5Y)
—
52-week high
—
52-week low
—
Change from 52-week high
—
Change from 52-week low
—
Annualized volatility
195.2%
Annualized volatility (3M)
104.2%
Beta
0.3
RSI (14D)
31.8
Price vs SMA 50
-21.3%
Price vs SMA 200
-57.8%
Avg volume (3M)
159,127
Relative volume
0.3
Average dollar volume
$375,699
Company
3 metricsSector
Healthcare
Industry
Medical Devices
Shares outstanding
3.03M
Valuation
12 metricsP / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
1.2×
reciprocal yield 81.9%
P / book
0.9
reciprocal yield 107.1%
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-241.1%
Historical valuation
8 metricsP / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—
Dividends & buybacks
7 metricsDividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—
Earnings calendar
2 metricsNext earnings
—
Last earnings
2024-10-30
Profitability
9 metricsGross margin
48.6%
Operating margin
-299.1%
Trailing 12 months
Net margin
-294.4%
Gross profit (TTM)
$2.05M
Operating profit (TTM)
−$12.61M
Net income (TTM)
−$12.41M
Trailing 12 months
Diluted EPS (TTM)
$-8.44
FCF margin
—
Effective tax rate
—
Growth
11 metricsRevenue growth YoY
+35.8%
Year over year
Net income growth YoY
—
Revenue (TTM)
$4.22M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+176.3%
Year over year · more shares
Revenue CAGR (3Y)
+49.7%
Revenue CAGR (5Y)
+16.3%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—
Quality
14 metricsReturn on equity
-225.2%
Return on assets
-103.9%
Debt / equity
—
Current ratio
1.4
EBITDA (TTM)
−$11.44M
Free cash flow (TTM)
—
Quick ratio
1.4
Interest coverage
-1,174.4
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$3.99M
Total assets
$11.94M
Total debt
$1.65M
Cash flow & spend
7 metricsOperating cash flow (TTM)
−$11.93M
Capital expenditures (TTM)
—
R&D (TTM)
—
SG&A (TTM)
—
Stock compensation (TTM)
$195,208
R&D / revenue
—
Stock compensation / revenue
4.6%
Ownership (13F)
3 metrics13F filers
8
13F filer change QoQ
-1
Institutional ownership
6.0%
Short interest
3 metricsShort interest
3.9%
Latest settlement · 1.0 days to cover
Days to cover
1.0d
Short-squeeze score
46 / 100
Insider activity
2 metricsNet insider buying (90D)
—
Insider-sentiment score
—
Risk flags
1 metricsGoing concern
Flagged